Cytomegalovirus vaccine - GlaxoSmithKline

Drug Profile

Cytomegalovirus vaccine - GlaxoSmithKline

Latest Information Update: 15 May 2007

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Cytomegalovirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 22 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 05 Jan 2000 Profile reviewed but no significant changes made
  • 18 Oct 1999 Ribi ImmunoChem has been integrated into Corixa Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top